document incorporate reference table part portion registrant annual report shareowners fiscal year iii portion registrant proxy statement annual meeting shareowner table table caption item business general segment business geographic area consumer pharmaceutical medical device diagnostic international raw material patent trademark seasonality competition research environment regulation property legal proceeding submission matter vote security holder executive officer registrant market registrant common equity relate shareowner matter select financial datum management discussion analysis financial condition result operation quantitative qualitative disclosure market risk financial statement supplementary data change disagreement account financial disclosure iii director executive officer registrant executive compensation security ownership certain beneficial owner management certain relationship relate transaction exhibit financial statement schedule report form signature report independent accountant exhibit index table form quarterly report available copy johnson johnson quarterly report form quarter current fiscal year exhibit provide charge shareowner submit write request secretary principal executive office company call report available day end quarter relate item business general johnson johnson employ approximately people worldwide engage manufacture sale broad range product health care field operate company conduct business virtually country world johnson johnson primary interest historically currently product relate human health wellbee johnson johnson organize state new jersey johnson johnson organized principle decentralize management executive committee johnson johnson principal management group responsible allocation resource company committee oversee coordinate activitie international company relate consumer pharmaceutical medical device diagnostic business international subsidiary exception manage citizen country locate segment business geographic areas johnson johnson worldwide business divide segment consumer pharmaceutical medical device diagnostic additional information require item incorporate reference narrative tabular graphic description segment geographic area caption management discussion analysis result operation financial condition segment business consumer pharmaceutical medical device diagnostic geographic area page johnson johnson annual report shareowner fiscal year consumer consumer segment principal product personal care hygienic product include nonprescription drug adult skin hair care product baby care product oral care product aid product sanitary protection product major brand include aveeno skin care product bandaid brand adhesive bandage benecol food product carefree panty shield clean clear teen skin care product imodium antidiarrheal johnson baby line product johnson skin hair care product lactaid lactoseintolerance product monistat remedy vaginal yeast infection adult child motrin ibuprofen product mylanta gastrointestinal product pepcid acid controller johnson johnson merck consumer pharmaceutical neutrogena skin hair care product tampon penaten natusan baby care products piz buin sundown sun care product reach toothbrush roc skin care product shower shower personal care product splenda noncaloric sugar substitute stayfree sanitary protection product broad family tylenol acetaminophen product viactiv calcium supplement product market principally general public distribute wholesaler directly independent chain retail outlet pharmaceutical pharmaceutical segment principal worldwide franchises antifungal antiinfective cardiovascular dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropicurology woman health field product distribute directly wholesaler use health care professional general public prescription drug antifungal field include nizoral ketoconazole sporanox itraconazole terazol terconazole daktarin miconazole nitrate antifungal product prescription drug antiinfective field include floxin ofloxacin levaquin levofloxacin prescription drug cardiovascular field include retavase reteplase recombinant biologic cardiology care product treatment acute myocardial infarction improve blood flow heart reopro abciximab treatment acute cardiac disease prescription drug dermatology field include retina micro tretinoin dermatological cream acne prescription drug gastrointestinal field include aciphex rabeprazole sodium sell outside pariet proton pump inhibitor treat erosive gastroesophageal reflux disease gerd symptomatic gerd duodenal ulcer imodium loperamide hcl antidiarrheal motilium domperidone gastrointestinal mobilizer remicade infliximab novel monoclonal antibody treatment certain crohn disease patient remicade indicate treatment rheumatoid arthritis prescription drug hematology field include procrit epoetin alfa sell outside eprex biotechnology derive version human hormone erythropoietin stimulate red blood cell production account company total revenue prescription drug immunology field include orthoclone okt muromonabcd reverse rejection kidney heart liver transplant prescription drug neurology field include reminyl galantamine topamax topiramate stugeron cinnarizine prescription drug oncology field include doxil doxorubicin anticancer treatment ergamisol levamisole hydrochloride colon cancer drug leustatin cladribine hairy cell leukemia prescription drug pain management field include duragesic fentanyl transdermal system sell abroad durogesic transdermal patch chronic pain ultracet tramadol hydrochlorideacetaminophen shortterm management acute pain ultram tramadol hydrochloride analgesic moderate moderately severe pain prescription drug psychotropic central nervous system field include risperdal risperidone haldol haloperidol antipsychotic drug concerta methylphenidate attention deficithyperactivity disorder prescription drug urology field include ditropan oxybutynin treatment overactive bladder prescription drug woman health field include orthonovum norethindroneethinyl estradiol tricilest norgestimateethinyl estradiol sell ortho tricyclen group oral contraceptive orthoprefest beta estradiolnorgestimate hormone replacement therapy sale distributor mckesson hboc cardinal distribution amerisourcebergen corp account respectively total revenue sale concentrated pharmaceutical segment medical device diagnostic medical device diagnostic segment include broad range product direction health care professional include suture mechanical wound closure product surgical equipment device wound management infection prevention product interventional diagnostic cardiology product diagnostic equipment supply joint replacement disposable contact lense product principally professional field physician nurse therapist hospital diagnostic laboratory clinic distribution market directly surgical supply dealer international international business johnson johnson conduct subsidiary locate country outside united states sell product country world product sell international business include describe business consumer pharmaceutical medical device diagnostic principal market product method distribution international business vary country culture product sell international business include develop united states develop subsidiary abroad investment activity country outside united states subject high risk comparable domestic activity investment commercial climate influence restrictive economic policy political uncertainty raw materialsraw material essential johnson johnson business generally readily available multiple source patent trademark johnson johnson practice obtain patent protection product process possible johnson johnson own license number patent relate product manufacturing process aggregate believe material importance operation business believe patent relate procritexprex single patent relate group patent material relation johnson johnson johnson johnson practice sell product trademark obtain protection trademark available mean johnson johnson trademark protect registration united states country product market johnson johnson consider trademark aggregate material importance operation business seasonality worldwide sale reflect significant degree seasonality spend heavy fourth quarter year quarter reflect increase spending decision principally advertise research grant competition product line johnson johnson company compete company large small locate united states abroad competition strong line regard number size compete company involve competition research involve development new product process improvement exist product process particularly significant result time time product process obsolescence development new improved product important johnson johnson success area business competitive environment require substantial investment continue research multiple sale force addition win retention customer acceptance johnson johnson consumer product involve heavy expenditure advertising promotion sell research research activity important segment johnson johnson business major research facility locate united states australia belgium brazil canada germany switzerland united kingdom cost johnson johnson worldwide research activity relate development new product improvement exist product technical support product compliance governmental regulation protection consumer amount million fiscal year respectively cost charge directly income year incur research sponsor johnson johnson environment past year johnson johnson subject variety federal state local environmental protection measure johnson johnson believe operation comply material respect applicable environmental law regulation johnson johnson compliance requirement expect material effect capital expenditure earning competitive position regulation johnson johnson business subject vary degree governmental regulation country operation conduct general trend regulation increase stringency united states drug device diagnostic cosmetic industry long subject regulation federal state local agency primarily product safety efficacy advertising labeling exercise broad regulatory power food drug administration fda continue result increase amount test documentationrequire fda clearance new drug device correspond increase expense product introduction similar trend product process regulation evident number major country outside united states especially european economic community effort continue harmonize internal regulatory system cost human health care continue subject study investigation regulation governmental agency legislative body united states countries united states attention focus drug price profit program encourage doctor write prescription particular drug recommend particular medical device absence new government regulation manage care potent force market place likely increase attention pay drug medical device price appropriate drug medical device utilization quality health care regulatory agency purview johnson johnson operate administrative power subject johnson johnson action product recall seizure product civil criminal sanction case johnson johnson deem advisable initiate product recall voluntarily item property johnson johnson worldwide subsidiary operate manufacturing facility occupy approximately million square foot floor space manufacturing facility industry segment johnson johnson business approximately follow table caption square foot segment thousand consumer pharmaceutical medical device diagnostic worldwide total table united states facility consumer segment pharmaceutical segment medical device diagnostic segment johnson johnson manufacturing operation outside united states conduct facility serve segment business location manufacture facility major geographic area world follow table caption number square feet geographic area facility thousands united states europe western hemisphere exclude usa africa asia pacific worldwide total table addition manufacturing facility discuss johnson johnson maintain numerous office warehouse facility world research facility discuss item business research johnson johnson generally seek manufacture facility principally location abroad lease office warehouse facility lease johnson johnson property maintain good operating conditionand repair utilize information lease obligation note rental expense lease commitment note consolidated financial statement johnson johnson annual report shareowner fiscal year segment information addition johnson johnson property plant equipment contain johnson johnson annual report shareowner fiscal year item legal proceeding information set forth note legal proceeding note consolidated financial statement johnson johnson annual report shareowner fiscal year incorporate reference company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund comparable state law primary relief seek cost past future remediation feasible predict determine outcome proceeding opinion company proceeding material adverse effect result operation cash flow financial position company item submission matter vote security holder applicable executive officer registrant list executive officer johnson johnson march indicate employee company affiliate hold position indicate past year family relationship executive officer arrangement understand executive officer person pursuant executive officer select annual meeting board director follow annual meeting shareowner executive officer elect board hold office year respective successor elect qualified early resignation removal information regard director company include follow executive officer director incorporate reference page johnson johnson proxy statement date march table caption age position robert darretta member board director member executive committee vice president finance russell deyo member executive committee vice president administrationa michael dormer member executive committee franchise group chairman medical devicesb roger fine member executive committee vice president general counselc colleen goggin member executive committee worldwide chairman consumer personal care groupd joann heffernan heisen member executive committee vice president chief information officere ralph larsen chairman board directors chief executive officer chairman executive committeef table table caption age position james lenehan vice chairman board directors member executive committee worldwide chairman medical device diagnostic group brian perkin member executive committee worldwide chairman consumer pharmaceutical nutritional groupg peterson phd member executive committee chairman research development pharmaceutical grouph christine poon member executive committee worldwide chairman pharmaceuticals groupi william weldon vice chairman board directors member executive committee robert wilson senior vice chairman board directors vice chairman executive committee table deyo join company associate general counsel member executive committee vice president administration dormer join company company group chairman worldwide franchise chairman depuy codman company acquire depuy inc time acquisition chief operating officer depuy inc dormer serve president depuy international ltd dormer member executive committee franchise group chairman medical devices february dormer expected name worldwide chairman medical device diagnostic group annual meeting board director fine join company member executive committee vice president administration vice president general counsel goggin join company hold position president personal product company name president johnson johnson consumer product company company group chairman north america johnson johnson consumer product goggin member executive committee worldwide chairman consumer personal care group june heisen join company treasurer controller member executive committee vice president chief information officer larsen assume present responsibility chairman board director chief executive officer larsen announce decision retire company july seek reelection board director annual meeting shareowner join company manufacturing trainee johnson johnson products inc hold numerous position company larsen appoint company group chairman appoint vice chairman executive committee chairman sector operating committee later larsen elect board director perkin join company hold position president mcneil consumer product company company group chairman otc pharmaceutical member executive committee worldwide chairman consumer pharmaceutical nutritional group peterson join company vice president drug discovery johnson pharmaceutical research institute name group vice president pharmaceutical research institute april president november peterson name chairman research development pharmaceuticals group peterson member executive committee august serve president johnson johnson pharmaceutical research development llc poon join company november company group chairman pharmaceuticals group poon member executive committee worldwide chairman pharmaceuticals group august prior join company serve management position bristolmyer squibb year recently president international medicine president medical devices item market registrant common equity relate shareowner matter information call item incorporate referenceto material caption management discussion analysis result operation financial condition common stock market price cash dividend pay johnson johnson annual report shareowner fiscal year item select financial datum information call item incorporate reference material caption summary operation statistical data johnson johnson annual report shareowner fiscal year item management discussion analysis financial condition result operation information call item incorporate reference narrative tabular graphic material include material caption management discussion analysis result operation financial condition page johnson johnson annual report shareowner fiscal year february board director approve stock repurchase program authorize company buy billion common stock open market march share repurchase pursuant program average share price repurchase program time limit suspend period discontinue item quantitative qualitative disclosure market risk information call item incorporate reference material caption management discussion analysis result operation financial condition financial instrument johnson johnson annual report shareowner fiscal year item financial statement supplementary datum information call item incorporate reference consolidate financial statement note thereto material caption independent auditor report page johnson johnson annual report shareowner fiscal year item change disagreement accountant account financial disclosure applicable iii item director executive officer registrant information call item incorporate reference material caption election director nominee page johnson johnson proxy statement date march material hereof caption executive officer registrant material caption section beneficial ownership report compliance johnson johnson proxy statement date march item executive compensation information call item incorporate reference follow section johnson johnson proxy statement date march election director director fee committee meeting page compensation committee report executive compensation page shareowner return performance graph executive compensation page item security ownership certain beneficial owner management information call item incorporate reference material caption election director stock ownershipcontrol page johnson johnson proxy statement date march item certain relationship relate transaction applicablepart item exhibit financial statement schedule report form follow document file report financial statement follow consolidated financial statement note thereto independent auditor report page johnson johnson annual report shareowner fiscal year incorporate reference consolidate balance sheet end fiscal year consolidated statement earning fiscal year consolidated statement equity fiscal year consolidated statement cash flow fiscal year note consolidated financial statement independent auditor report financial statement schedule schedule valuation qualifying account schedule list omit require applicable exhibit require file item regulation information call item incorporate reference exhibit index report report form report form file october include press release announce company sale earning fiscal quarter end september report form file november include press release announce completion company acquisition inverness medical technology inc diabetes care product business report form file november amend form file november johnson johnson subsidiaries schedule valuation qualifying account fiscal year end december december january dollar million table caption addition balance charge deduction reserve balance begin cost end period expensesb description period reserve deduct account receivable trade reserve doubtful account writeoff recovery currency adjustment reserve customer rebate customer rebate allow currency adjustment reserve cash discount cash discount allow currency adjustment reserve deduct account receivable trade reserve doubtful account writeoff recovery currency adjustment reserve customer rebate customer rebate allow currency adjustment reserve cash discount cash discount allow currency adjustment reserve deduct account receivable trade reserve doubtful account writeoff recovery currency adjustment reserve customer rebate customer rebate allow currency adjustment reserve cash discount cash discount allow table schedule prepare retroactive effect merger johnson johnson alza june charge relate customer rebate cash discount reflect reduction sale customer signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize date march johnson johnson registrant larsen larsen chairman board directors chief executive officer pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate table caption signature title date larsen chairman board director march chief executive officer larsen director principal executive officer darretta vice president finance march director principal financial darretta officer cosgrove controller march cosgrove burrow director march burrow cooney director march cooney cullen director march cullen folkman director march folkman jordan director march jordan langbo director march langbo table table caption signature title date lenehan vice chairman board directors march director lenehan mayo director march mayo mullin director march mullin schacht director march schacht singer director march singer snow director march snow weldon vice chairman board director march director weldon wilson senior vice chairman board march directors director wilson table report independent accountant financial statement schedule shareowner board directors johnson johnson audits consolidated financial statement refer report date january appear johnson johnson annual report shareowner fiscal year end december report consolidate financial statement incorporate reference annual report include audit financial statement schedule list item opinion financial statement schedule present fairly material respect information set forth read conjunction relate consolidated financial statement pricewaterhousecooper llp pricewaterhousecooper llp new york new york january exhibit index table caption reg exhibit table description item exhibit restate certificate incorporation date april incorporate reference exhibit registrant annual report year end december aii certificate amendment restate certificate incorporation company date incorporate reference exhibit registrant annual report year end january aiii certificate amendment restate certificate incorporation company date incorporate reference exhibit aiii registrant annual report year end december aiv certificate amendment restate certificate incorporation company effective incorporate reference exhibit registrant form quarterly report quarter end july bylaw company amend effective june incorporate reference exhibit registrant form quarterly report quarter end july request security exchange commission registrant furnish copy instrument define right holder long term debt registrant stock option plan nonemployee director incorporate reference exhibit registrant annual report year end december stock option plan incorporate reference exhibit registrant annual report year end december stock option plan amend incorporate reference exhibit registrant annual report year end january stock option plan amend incorporate reference exhibit registrant annual report year end december stock compensation plan incorporate reference exhibit registrant annual report year end december executive incentive plan amend incorporate hereinby reference exhibit registrant annual report year end december domestic deferred compensation certificate extra compensation plan amend file document defer fee plan director amend incorporate reference exhibit registrant annual report year end december executive income deferral plan amend incorporate reference exhibit registrant annual report year end january excess saving plan incorporate reference exhibit registrant annual report year end december supplemental retirement plan incorporate reference exhibit registrant annual report year end january executive life insurance plan incorporate reference exhibit registrant annual report year end january table table caption reg exhibit table description item exhibit stock option gain deferral plan incorporate reference exhibit registrant annual report year end january estate preservation plan incorporate reference exhibit registrant annual report year end january statement computation ratio earning fix charge file document page company annual report shareowner fiscal year portion annual report incorporate reference report deem file file document subsidiary file document consent independent accountant file document annual report form johnson johnson saving plan file june cautionary statement pursuant private security litigation reform act safe harbor forwardlooke statement file document table management contract compensatory plan arrangement require file exhibit form pursuant item report copy exhibit list provide charge shareowner submit write request specify desire exhibit secretary principal executive office company text document document typeexg sequence filenameyexgtxt descriptiondomestic defer compensation plan amend text exhibit johnson johnson certificate extra compensation planwitnesseth johnson johnson company wish reward employee employee subsidiarie employee faithful service past particularly encourage employee future work permit employee share growth success company enterprise issue share certificate extra compensation cec share end receive extra compensation sum base measure cash dividend time time declare equal number share common stock company common stock formula value cec share establish pursuant article ninth plan formula value time termination employment death employment consideration premise promise contain long employee shall remain employee agree number cec share designate employee extra compensation shall base aggregate number cec share award employee accordance plan evidence write record company second employee remain employee company shall pay employee date pay cash dividend company common stock sum equivalent cash dividend multiply total number cec share designate employee event employee death employee company shall pay employee beneficiary record employee signature record company sum money shall determined percentage formula value cec share percentage shall base period elapse date cec share award death follow event death eighteen month date award event death eighteen month fortytwo month date award event death fortytwo month date award event termination employee employment retirement physical mental disability reason death company shall pay employee sum money shall determined percentage formula value cec share purpose plan employee place longterm disability consider employee percentage shall base period elapse date cec share award termination employment follow event termination month date award event termination month twentyfour month date award event termination twentyfour month thirtysix month date award event termination thirtysix month fortyeight month date award event termination fortyeight month month date award event termination month date award company shall pay sum money article single lump sum employee duly elect pursuant provision article seventh defer receipt sum hisher retirement fourth election employee provide payment sum employee hisher retirement deferred pay single lump sum installment lump sum payment defer taxable year follow employee retirementdate installment payment elect installment payment immediately retirement defer taxable year installment payment annually manner describe approximately equal installment amount value cec payout balance plus accrued interest divide number remain installment minimum number annual installment maximum number employee elect defer value hisher total cec holdings retirement percentage increment follow rule shall apply respect payment immediate lump sum payment employee receive value hisher cec holdings calendar month hisher retirement effective date employee retire prior determination prior year cec value receive estimate value remainder pay shortly final value determine defer lump sum payment employee receive value hisher cec holding plus accrued interest january year heshe elect receive payment immediate commencement installment employee receive installment calendar month hisher retirement effective date subsequent installment plus accrue interest pay january year defer commencement installment employee receive subsequent installment plus accrue interest january year fifth respect payment defer andor pay installment interest shall pay company effective date retirement date payment interest rate defer andor installment payment employee shall fix date retirement shall rate rounded decimal place offer report wall street journal effective retirement date united states treasury instrument period comparable length period deferral andor installment payment interest shall compound semiannually calendar day june december year instrument quote average rate shall utilize way example election receive installment year comparable year treasury rate shall utilize election defer commencement installment year installment pay year comparable year treasury rate shall utilize established interest rate shall remain fix period deferral sixth event death employee prior termination hisher employment company payment balance plus accrued interest soon administratively practical single lump sum payment designate beneficiary event deferral installment election total cec holding pay accordance provision paragraph article fourth lump sum payment soon practical follow employee retirement effective date seventh election employee defer payment elect installment hisher cec holding hisher effective retirement date minimum month prior date retirement date election revise revoke month prior retirement date month period prior retirement date election irrevocable revoke revise company disallow employee desire defer payment andor elect installment determine participation jeopardize plan compliance applicable law plan status hat plan erisa notwithstanding exception employee retirement effective date january june employees deferral andor installment election minimum month calendar year prior retirement date example employee retire january deferral andor installment election later september retirement date election later december respect retirement occur july december election prior december election defer andor receive installment payment revise revoke prior permissible date make election time election revoke revise election defer payment andor pay installment effective file administrator refer article fifteenth form utilize purpose election require deadline shall disregard election defer andor pay installment consultation employee tax andor financial advisor eighth number cec share designate base measured extra compensation employee shall increase proportionately time time extent stock split dividend common stock declare pay issue outstanding common stock company likewise number cec share shall reduce proportionately time time extent number cec share issue outstanding common stock company reduce reorganization reduction capital ninth purpose article agreement formula value cec share shall determine company board director shall event mention determine formula value sum onehalf asset value share common stock plus onehalf earningpower value share common stock calculate follow sum onehalf consolidated net asset value share common stock asset share liability include reserve surplus reserve share asset liability appear book company subsidiary fiscal year end immediately precede date valuation plus onehalf consolidated earningpower value share common stock determine average annual net earning share common stock taxis net earning appear book company subsidiary fiscal year precede date valuation capitalize return capital invest percent multiple onehalf time average earning share purpose forego calculation book company subsidiary shall conclusive method consolidation shall adopt company prepare previous annual report stockholder include appropriate provision taxis foreign domestic incur remit income subsidiary company decision company treasurer time time time procedure adopt maintain book company subsidiary preparation balance sheet income statement method adjustment consolidation matter accounting practice procedure shall conclusive event shall opinion board director company calculation provide result true value date article determination necessary board shall obligate vary formula extent modify multiple average earning share shall multiply board director shall fifteenth year determine announce formula value company common stock immediately precede fiscal year end purpose plan tenth dividend share value measure extra compensation pay hereunder contain shall construe agreement transfer employee hisher beneficiary shall acquire virtue hisher award cec share right title interest whatsoever company common stock eleventh right benefit cec share award plan assignable company fund obligation create employee participation cec plan company make unsecured promise pay obligation general corporate asset apply obligation active retire participant commencing award year end certificate represent cec share long issue instead number cec share award shall record book company twelfth regular parttime employee work hour week shall consider employee plan change parttime status ofless hour week shall consider termination provide event employee age employee shall purpose plan deem retire contain plan shall construe alter present employment indefinite term terminable employee company prior advance notice thirteenth employee leave company subsidiary request company work joint venture operation company subsidiary minority partnership interest sole discretion management compensation committee consider employee solely purpose plan period year follow departure company arrangement extended additional year management compensation committee sole discretion determine good interest company person cease employment joint venture operation concomitant return employment company subsidiary person shall immediately consider terminate cease consider employee purpose plan fourteenth employee designate beneficiary receive value hisher payout death beneficiary predecease employee beneficiary name designate beneficiary employee payout balance case distribute employee estate beneficiary designation revise time submit beneficiary designation form company beneficiary beneficiary indicate form shall supersede prior designation include designation appear certificate represent cec share fifteenth quarter calendar year statement send active employee participate cec plan retiree defer cec holding report active employee provide value cec holding base prior year final cec value statement include previously deferral election beneficiary designation report retiree provide defer cec payout balance plus interest defer andor installment election beneficiary designation sixteenth cec plan administer extra compensation services department corporate headquarters company question regard administration cec plan address text document document typeex sequence filenameyextxt descriptionstatement computation ratio earning text exhibit johnson johnson subsidiaries statement computation ratio earning fix charge dollar million table caption fiscal year end december december january january december determination earning earning provision taxis income fix charge total earning define fix charge rent interest fix charge capitalize interest total fix charge ratio earning fix charge table ratio earning fix charge represent historical ratio johnson johnson calculate total enterprise basis ratio compute dividing sum earning provision taxis fix charge exclude capitalize interest fix charge fix charge represent interest include capitalize interest amortization debt discount expense interest factor rental consist appropriate interest factor operating lease earning year end january include charge relate restructuring million inprocess research development charge million exclude effect charge ratio earning fix charge text document document typeex sequence filenameyextxt descriptionpage company annual report text management discussion analysis result operation financial condition overview record sale billion exceed sale billion mark year consecutive positive sale growth growth lead strong performance pharmaceutical medical device diagnostic segment company complete merger alza corporation researchbase pharmaceutical company innovative drug delivery technology complete acquisition inverness medical technology supplier lifescan electromechanical product investment company continue commitment build strong science technologybase business balance sheet remain strong cash generate worldwide operation record billion cash dividend share pay shareowner increase represent consecutive year cash dividend increase company continue company triple credit rating company objective achieve superior level capital efficient profitable growth accomplish company management operate business consistent certain strategic principle prove successful time end company participate growth area human health care commit attain leadership position growth segment development innovative product service billion sale invest research development recognize importance ongoing development new differentiate product service company system management operate decentralize basis operating company locate country company view management philosophy asset fundamental success broadly base business foster entrepreneurial spirit combine extensive resource large organization ability react quickly local market change challenge business manage long term order sustain leadership position achieve growth provide endure source value shareowner unify management team company dedicated employee achieve objective johnson johnson credo credo provide common set value serve constant reminder company responsibility customer employee communitie shareowner thecompany believe basic principle overall mission improve quality life people enable johnson johnson continue leader health care industry description business company subsidiarie employee worldwide engage manufacture sale broad range product health care field company conduct business virtually country world company primary interest historically currently product relate human health wellbee company organize principle decentralize management executive committee johnson johnson principal management group responsible operation allocation resource company committee oversee coordinate activitie domestic international company span consumer pharmaceutical medical device diagnostic business international subsidiary exception manage citizen country locate product line company compete company large small locate united states america abroad competition strong line regard number size compete company involve competition research involve development improvement new exist product process particularly significant result time time product process obsolescence development new improve product important company success area business competitive environment require substantial investment continue research multiple sale force addition win retention customer acceptance company consumer product involve heavy expenditure advertising promotion sell sale customer bar graph sale customer million dollar table caption domestic international table sale earning worldwide sale increase billion compare increase sale distributor mckesson hboc cardinal distribution amerisourcebergen corp account respectively total revenue exclude impact foreign currency worldwide sale increase net earning bar graph net earning million dollar table caption earning table result exclude restructure inprocess charge worldwide net earning billion reflect increase worldwide net earning share equal share increase net earning share exclude impact special charge worldwide net earning billion net earning share represent increase respectively aftertax special charge take include million relate alza merger complete june million inprocess research development iprd cost associate acquisition inverness medical technology teramed inc complete fourth quarter worldwide net earning billion reflect increase worldwide net earning share equal share increase net earning share exclude impact special charge worldwide net earning billion net earning share represent increase respectively special charge take include iprd cost associate acquisitions atrionix inc crescendo million net favorable adjustment million cost associate global manufacturing restructure charge income expense include gain relate sale certain equity security worldwide net earning billion reflect increase worldwide net earning share equal share increase net earning share exclude impact special charge worldwide net earning billion net earning share represent increase respectively special charge include cost associate centocor sequus merger reconfiguration worldwide manufacture network iprd charge average diluted share common stock outstanding billion sale domestic company billion billion billion represents increase sale international company billion billion billion represent increase exclude impact foreign currency fluctuation past year international company sale increase geographic area world post operational gain exclude effect exchange rate fluctuation dollar foreign currency sale increase europe western hemisphere exclude asiapacific africa region company achieve annual compound growth rate worldwide sale year period domestic sale grow rate international sale grow rate worldwide net earning achieve year annual growth rate earning share grow rate year annual compound growth rate sale annual compound growth rate net earning annual compound growth rate earning share exclude impact foreign currency fluctuation annual compound growth rate sale year period year period respectively distribution sale revenue distribution sale revenue table caption employment cost cost material service depreciation amortization property intangible tax payroll earning reinveste business cash dividend pay special chargesiprd table cost expense research activity represent significant company business expenditure relate development new product improvement exist product technical support product compliance governmental regulation protection consumer worldwide cost research activity exclude special charge iprd follow table caption million dollar research expense percent increase prior year percent sale table research expense percent sale pharmaceutical segment average segment respectively research expense bar graph table caption research expense million dollar expense table advertising expense comprise television radio print medium internet advertising billion billion billion company believe operation comply material respect applicable environmental law regulation company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund comparable state law primary relief seek cost past future remediation feasible predict determine outcome proceeding opinion company proceeding material adverse effect result operation cash flow financial position company worldwide sale reflect significant degree seasonality spend heavy fourth quarter year quarter reflect increase spending decision principally advertise research grant worldwide effective income tax rate refer note additional information segment business financial information company worldwide business segment summarize note additional information segment business sale segment business bar graphtable caption sale segment business million dollar consumer pharmaceutical medical device diagnostic total table table caption sale increase millions dollar percent consumer pharmaceutical med devices diag worldwide total table operate profit segment business bar graph table caption operate profit segment business million dollar consumer pharmaceutical med devices diag worldwide total table result include special charge relate alza merger inprocess research development exclude charge operate profit percentage sale pharmaceutical segment medical device diagnostic segment result include special charge relate inprocess research development gain related restructuring exclude charge operate profit percentage sale consumer segment pharmaceutical segment medical device diagnostic segment result include special charge relate centocor sequus merger exclude charge operate profit percentage sale pharmaceutical segment table caption operate profit percent sale million dollar consumer pharmaceutical med devices diag segment total expense allocate segment earning taxis income table result include special charge relate alza merger inprocess research development exclude charge operate profit percentage sale pharmaceutical segment medical device diagnostic segment result include special charge relate inprocess research development gain related restructuring exclude charge operate profit percentage sale consumer segment pharmaceutical segment medical device diagnostic segment consumer consumer segment principal product personal care hygienic product include nonprescription drug adult skin hair care product baby care product oral care product aid product sanitary protection product major brand include neutrogena skin hair care product aveeno skin care product bandaid brand adhesive bandage benecol food product carefree panty shield clean clear teen skin care product imodium antidiarrheal johnson baby line product johnson skin hair care product monistat remedy vaginal yeast infection adult child motrin analgesic product mylanta gastrointestinal product pepcid acid controller johnson johnson merck consumer pharmaceutical tampon penaten natusan baby care products piz buin sundown sun care product reach toothbrush roc skin care product shower shower personal care product splenda noncaloric sugar substitute stayfree sanitary protection product broad family tylenol acetaminophen product product market principally general public distribute wholesaler directly independent chain retail outlet consumer segment sale billion increase domestic sale increase international sale gain local currency offset negative currency impact consumer sale experience strong growth mcneil nutritional splenda sweetener product recently acquire viactiv brand calcium supplement solid growth achieve skin care franchise include neutrogena roc aveeno clean clear product line fourth quarter company introduce neutrogena man line consist premium skin care product provide dermatologist test clinically prove solution man skin care problem consumer segment sale billion increase domestic sale increase international sale gain local currency offset negative currency impact consumer sale lead continued strength skin care franchise include neutrogena roc aveeno clean clear product line strong performance johnson line baby skin care product company acquire joseph aspirin business acquisition entry cardioprotective aspirin market mcneil consumer specialty pharmaceutical world leader overthecounter analgesic consumer segment sale billion increase domestic sale increase international sale decline international sale gain local currency offset negative currency impact company launch product include benecol dietary ingredient stanol ester aids reduction cholesterol complete acquisition aveeno brand product pharmaceutical pharmaceutical segment principal worldwide franchises antifungal antiinfective cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management psychotropic central nervous system urology field product distribute directly wholesaler use health care professional general public prescription drug antifungal field include nizoral ketoconazole sporanox itraconazole terazol terconazole daktarin miconazole nitrate antifungal product prescription drug antiinfective field include floxin ofloxacin levaquin levofloxacinprescription drug cardiovascular field include retavase reteplase recombinant biologic cardiology care product treatment acute myocardial infarction improve blood flow heart reopro abciximab treatment acute cardiac disease prescription drug contraceptive field include orthonovum norethindroneethinyl estradiol tricilest norgestimateethinyl estradiol sell ortho tricyclen group oral contraceptive prescription drug dermatology field include retina micro tretinoin dermatological cream acne prescription drug gastrointestinal field include aciphex rabeprazole sodium sell outside pariet proton pump inhibitor treat erosive gastroesophageal reflux disease gerd duodenal ulcer imodium loperamide hcl antidiarrheal motilium domperidone gastrointestinal mobilizer remicade infliximab novel monoclonal antibody treatment certain crohn disease patient remicade indicate treatment rheumatoid arthritis prescription drug hematology field include eprex epoetin alfa sell procrit biotechnology derive version human hormone erythropoietin stimulate red blood cell production prescription drug immunology field include orthoclone okt muromonabcd reverse rejection kidney heart liver transplant prescription drug neurology field include topamax topiramate reminyl galantamine stugeron cinnarizine prescription drug oncology field include doxil doxorubicin anticancer treatment ergamisol levamisole hydrochloride colon cancer drug leustatin cladribine hairy cell leukemia prescription drug psychotropic central nervous system field include antipsychotic drug risperdal risperidone haldol haloperidol concerta methylphenidate attention deficit hyperactivity disorder prescription drug pain management field include duragesic fentanyl transdermal system sell abroad durogesic transdermal patch chronic pain ultram tramadol hydrochloride analgesic moderate moderately severe pain prescription drug urology field include ditropan oxybutynin treatment overactive bladder johnson johnson markets prescription drug world sale generate outside united states america thirtythree drug sell company sale excess million excess million pharmaceutical segment sale billion increase include growth domestic sale operationally international sale increase partially offset negative currency impact worldwide sale gain local currency partially offset negative currency impact sale growth reflect strong performance procriteprex risperdal duragesic concerta remicade ultram topamax aciphexpariet sales procriteprex account total company revenue fourth quarter company receive food drug administration fda approval ortho evra birth control patch ortho evra thin beige patch deliver continuous level hormones norelgestromin ethinyl estradiol progestin estrogen respectively skin bloodstream patch wear week time replace day week consecutive week fourth week patchfree company file new drug application fda december include levaquin treatment nosocomial pneumonia orally disintegrate formulation risperdal synthetic oral solution reminyl alzheimer disease pharmaceutical segment sale billion increase include growth domestic sale operationally international sale increase offset negative currency impact worldwide sale gain local currency partially offset negative currency impact sale growth reflect strong performance procriteprex risperdal duragesic levaquin remicade ultram topamax aciphexpariet oral contraceptive line product sale growth partially offset restrict access limited indication propulsidprepulsid number market world pharmaceutical segment sale billion increase include growth domestic sale international sale increase sale gain local currency offset negative currency impact worldwide growth reflect strong performance procrit risperdal duragesic levaquin oral contraceptive line product significant research activity continue pharmaceutical segment increase billion sale representsan increase compound annual growth rate approximately fiveyear period johnson johnson pharmaceutical research development llc know janssen research foundation johnson pharmaceutical research institute worldwide pharmaceutical research organization additional research conduct centocor alza collaboration james black foundation london england medical device diagnostic medical device diagnostic segment include broad range product direction health care professional include suture mechanical wound closure product surgical equipment device wound management infection prevention product interventional diagnostic cardiology product diagnostic equipment supply joint replacement disposable contact lense product principally professional field physician nurse therapist hospital diagnostic laboratory clinic acquisition medical device diagnostic segment recent year integral ongoing process transform segment principally medical supply business serve range high technology medical specialty worldwide sale billion medical device diagnostic segment represent increase domestic sale international sale increase sale gain local currency offset negative currency impact worldwide sale gain local currency reduce strength dollar strong sale growth cordis circulatory disease management product depuy orthopaedic joint reconstruction spinal product ethicon wound closure surgical sport medicine woman health product ethicon endosurgery minimally invasive surgical vascular access product lifescan blood glucose monitoring product primary contributor medical device diagnostic segment growth fourth quarter cordis announce fda approval velocity coronary stent hepacoat raptorrail stent delivery system rapid exchange stent coat heparin bloodthinne agent reduce risk clot formation addition cordis complete acquisition teramed inc privately hold company develop proprietary catheterbase system treatment abdominal aortic aneurysm november company complete acquisition inverness medical technology manufacturer developer advance blood glucose monitoring product inverness wholly own subsidiary johnson johnson johnson johnson lifescan business unit form lead blood glucose monitor franchiseinverness medical technology acquire order provide technology development future product additionally vistakon introduce acuvue colour brand contact lense provide exceptional comfort handle soft frequent replacement color contact lens acuvue colours twoweek daily wear lens available vision correction seven naturallooke color unique colourswrappedincomfort design eliminate color touch eye offer natural color depth worldwide sale billion medical device diagnostic segment represent increase domestic sale international sale increase sale gain local currency offset negative currency impact worldwide sale gain local currency reduce strength dollar strong sale growth cordis coronary endovascular stent depuy spinal product ethicon mitek suture anchor gynecare woman health product ethicon endosurgery mammotome breast biopsy system ultracision harmonic scalpel vistakon disposable contact lens product primary contributor medical device diagnostic segment growth worldwide sale billion medical device diagnostic segment represent increase domestic sale increase international sale gain local currency partially offset strength dollar fourth quarter cordis launch new velocity coronary stent europe receive medical community ethicon new product include pronova poly hexafluoropropylenevdf suture synthetic nonabsorbable monofilament cardiovascular vascular surgery surgifoam absorbable gelatin sponge usp prove surgery year europe givenethicon line hemostasis product ethicon receive approval gynecare thermachoice uterine balloon therapy system latexfree generation ablation technology system excessive uterine bleed geographic area company sale major geographic area present table caption sale increase millions dollar percent united states europe western hemisphere exclude asiapacific africa worldwide total table international sale negatively impact translation local currency operating result dollar region average exchange rate dollar decline year note additional information geographic area sale geographic area business bar graph sale geographic area business million dollar table caption united states europe western hemisphere exclude asiapacific africa total sale dollar table liquidity capital resource cash generate operation select borrowing provide major source fund growth business include work capital addition property plant equipment acquisition cash current marketable security total billion end compare billion end year end december change time salary increase bonus employee december february change enact result finalize order align compensation performance result change increase approximately million accrue salary wage commission balance sheet december result correspond increase cash flow operating activity total unused credit available company approximate billion include billion credit commitment bank worldwide expire october company shelf registration file security exchange commission enable company issue billion unsecured debt security warrant purchase debt security medium term note mtn program mtns issue december company billion remain shelf registration company continue company triple credit ratingtotal borrowing end billion billion respectively net cash cash current marketable security net debt billion net cash cash current marketable security net debt billion total debt represent total capital shareowner equity total debt total capital shareowner equity share end compare yearend increase period end december material cash commitment summary borrowing find note february company announce stock repurchase program billion time limit program financial instrument company use financial instrument manage impact foreign exchange rate change cash flow accordingly company enter forward foreign exchange contract protect value exist foreign currency asset liability hedge future foreign currency product cost gain loss contract offset gain loss underlie transaction appreciation dollar december market rate increase unrealized value company forward contract million conversely depreciation dollar december market rate decrease unrealized value company forward contract million scenario gain loss forward contract offset gain loss underlie transaction impact future earning cash flow company enter currency swap contract manage company exposure change currency exchange rate hedge foreign currency denominate asset liability impact change interest rate company interest rate sensitive financial instrument immaterial company enter financial instrument trade speculative purpose company policy enter contract party equivalent credit rating counterpartie contract major financial institution company significant exposure counterparty management believe risk loss remote change price inflation johnson johnson aware product set decade policymaker consumer business express concern rise cost health care response concern johnson johnson longstanding policy pricing product responsibly period united states weight average compound annual growth rate johnson johnson price increase health care product prescription overthecounter drug hospital professional product consumer price index cpi period inflation rate moderate part world continue effect worldwide economy consequently way company operate face increase cost company strive maintain profit margin cost reduction program productivity improvement periodic price increase key accounting policy new accounting pronouncement previously describe company engage manufacture sale product healthcare field nature business unlikely accounting policy open interpretation material effect company result operation certain key accounting policy affect result company time revenue recognition fact research development expense expense incur note consolidated financial statement describe company significant accounting policy emerge issue task force eitf reach consensus account certain sale incentive eitf address recognition measurement statement earning classification certain sale incentive additionally eitf issue vendor income statement characterization consideration pay resell vendor product eitf address classification statement earning consideration vendor entity purchase vendor product resale pronouncement effective begin quarter impact pronouncement company financial statement result correspond reduction sale expense estimate million million million respectively eitf million million million respectively eitf june financial accounting standard board fasb issue pronouncement sfas business combination sfas require purchase method accounting business combination initiate june eliminate use poolingofinterest method accounting sfas clarify criterion recognition intangible asset separately goodwill sfas goodwill intangible asset sfas effective january issue fasb june sfas eliminate amortization goodwill indefinitelive intangible asset initiate annual review impairment identifiable intangible asset determinable useful life continue amortize amortization goodwill intangible asset acquire prior june eliminate adoption sfas rule establish sfas apply immediately goodwill intangible asset acquire june note additional information june fasb issue sfas accounting asset retirement obligation address accounting reporting entity legal obligation associate retirement longlive asset acquisition development normal operation asset pronouncement effective fiscal year begin june october fasb issue sfas accounting impairment disposal longlive asset sfas effective quarter sfas address financial accounting reporting impairment disposal longlive asset sfas supersede sfas accounting impairment longlive asset longlive asset dispose accounting reporting provision accounting principle board opinion reporting result operationsreporte effect disposal segment business extraordinary unusual infrequently occur event transaction segment business dispose previously define opinion implementation sfas sfas expect material effect company result operation cash flow financial position common stock market price company common stock list new york stock exchange symbol jnj composite market price range adjust stock split effective johnson johnson common stock table caption high low high low quarter second quarter quarter fourth quarter yearend close table cash dividend pay company increase dividend consecutive year cash dividend pay share compare dividend share share dividend distribute follow table caption cfirst quarter second quarter quarter fourth quarter total table january board director declare regular cash dividend share pay march shareowners record february company expect continue practice pay regular cash dividend cautionary factor affect future result annual report contain forwardlooke statement forwardlooke statement relate strictly historical current fact anticipate result base management plan subject uncertainty forwardlooke statement identify use word like plan expect anticipate estimate word similar meaning conjunction thing discussion future operation financial performance company strategy growth product development regulatory approval market position expenditure forwardlooke statement base current expectation future event company guarantee forwardlooke statement accurate company believe reasonable expectation assumption investor realize underlying assumption prove inaccurate unknown risk uncertainty materialize actual result vary materially company expectation projection investor caution place undue reliance forwardlooke statement furthermore company assume obligation update forwardlooke statement result new information future event development company report year end december file march contain exhibit discussion factor cause actual result differ expectation prior file investor reference company report fiscal year end december company note factor permit private security litigation reform act consolidated balance sheet johnson johnson subsidiaries table caption december december dollar million note asset current asset cash cash equivalent note marketable security note account receivable trade allowance doubtful account inventory note defer taxis income note prepay expense receivables total current asset marketable security noncurrent note property plant equipment net note intangible asset net note defer taxis income note asset total asset liabilitie shareowner equity current liabilitiesloans note payable note account payable accrue liability accrue salary wages commission taxis income total current liability longterm debt note defer tax liability note employee relate obligation note liabilitie shareowner equity prefer stock par value authorize unissued share common stock par value share note authorize share issue share note receivable employee stock ownership plan note accumulate comprehensive income note retain earning common stock hold treasury cost note total shareowner equity total liability shareowner equity table note consolidated financial statement consolidate statement earning johnson johnson subsidiaries table caption dollar million share figure note sale customer cost product sell gross profit selling marketing administrative expense research expense purchase inprocess research development note interest income interest expense net portion capitalize note income expense net earning provision taxis income provision taxis income note net earning basic net earning share note dilute net earning share note table note consolidated financial statement consolidate statement equity johnson johnson subsidiaries table caption note receivable accumulate common employee stock treasury comprehensive retain stock ownership comprehensive issue stock dollar million note total income earning plan esop income balance january net earning cash dividend pay employee compensation stock option plan repurchase common stock business combination comprehensive income net tax currency translation adjustment unrealize gain loss security reclassification adjustment total comprehensive income note receivable esop balance january net earning cash dividend pay employee compensation stock option plan conversion subordinate debenture repurchase common stock business combination comprehensive income net tax currency translation adjustment unrealize gain loss security pension liability adjustment reclassification adjustment total comprehensive income note receivable esop balance december net earning cash dividend pay employee compensation stock option plan conversion subordinate debenture repurchase common stock business combination comprehensive income net tax currency translation adjustment unrealize gain loss security pension liability adjustment gainslosse derivative hedge reclassification adjustment total comprehensive income note receivable esop balance december table note consolidated financial statement consolidate statement cash flow johnson johnson subsidiaries table caption dollar million note cash flow operating activity net earning adjustment reconcile net earning cash flow depreciation amortization property intangible purchase inprocess research development increase defer taxis account receivable reserve change asset liability net effect acquisition business increase account receivable increase decrease inventory increase account payable accrue liability increase decrease current noncurrent asset increase current noncurrent liability net cash flow operating activity cash flow invest activity addition property plant equipment proceed disposal asset acquisition business net cash acquire note purchase investment sale investment net cash investing activity cash flow financing activity dividend shareowner repurchase common stock proceed shortterm debt retirement shortterm debt proceed longterm debt retirement longterm debt proceed exercise stock option net cash financing activity effect exchange rate change cash cash equivalent decreaseincrease cash cash equivalent cash cash equivalent begin year note cash cash equivalent end year note supplemental cash flow datum cash pay year interest income taxis supplemental schedule noncash investing financing activity treasury stock issue employee compensation stock option plan net cash proceed conversion debt acquisition business fair value asset acquire fair value liability assume treasury stock issue fair value net cash pay acquisition table note consolidated financial statement note consolidated financial statement summary significant accounting principle basis presentation consolidate financial statement johnson johnson prepare retroactive effect merger alza corporation alza june principle consolidation financial statement include account johnson johnson subsidiaries intercompany account transaction eliminate cash equivalent company consider security maturity month purchase cash equivalent investment shortterm marketable security carry cost approximate fair value longterm debt security company ability intent hold maturity carry amortize cost approximate fair value investment classified availableforsale carry estimate fair value unrealize gain loss record component accumulate comprehensive income management determine appropriate classification investment debt equity security time purchase reevaluate determination balance sheet date property plant equipment depreciation property plant equipment state cost company utilize straightline method depreciation estimate useful life asset table building building equipment year land leasehold improvement year machinery equipment year table revenue recognition company recognize revenue product sale good ship deliver title pass customersale incentive trade promotional allowance company currently recognize expense relate coupon certain sale incentive trade promotion issuance classifie expense sell marketing administrative expense company adopt eitf issue effective begin quarter impact company reclassification expense reduction sale million million million eitf million million million eitf shipping handling shipping handling cost incur million million million respectively include sell marketing administrative expense revenue receive shipping handle immaterial period present inventory inventory state low cost market determine firstin firstout method intangible asset acquisition complete june excess cost fair value net asset purchase business record goodwill amortize straightline basis period year cost acquire intangible amortize straightline basis estimate useful life company continually evaluate carry value goodwill intangible asset impairment recognized expect future operating cash flow derive intangible asset carrying value company adopt sfas business combination sfas goodwill intangible asset business combination consummate july account accordance new pronouncement goodwill relate acquisition complete subsequent june amortize subject impairment testing addition effective january company long require amortize goodwill certain intangible asset relate acquisition complete prior july financial instrument effective january company adopt sfas accounting derivative instrument hedge activity amend sfas account certain derivative instrument certain hedging activity amendment fasb statement collectively refer sfas sfas require derivative instrument record balance sheet fair value change fair value derivative record period current earning comprehensive income depend derivative designate hedge transaction depend type hedge transaction company use forward exchange contract manage exposure variability cash flow primarily relate foreign exchange rate change future product purchase denominate foreign currency company use currency swap manage currency risk primarily relate borrowing type derivative designate cash flow hedge additionally company use forward exchange contract offset exposure certain foreign currency asset liabilitie forward exchange contract designate hedge change fair value derivative recognize earning offset current earning effect relate foreign currency asset liability designation cash flow hedge later date enter derivative contract january inception derivative expect highly effective change fair value derivative designate cash flow hedge highly effective record accumulate comprehensive income underlie transaction affect earning reclasse earning account hedge transaction fair value forward exchange contract represent present value change forward exchange rate times notional derivative fair value currency swap contract determine discount present future cash flow currency exchange interest rate prevail market period currencyexchange express result dollar current spot foreign currency exchange rate inception ongoing basis company assess derivative expect highly effective offset change cash flow hedge item derivative long expect highly effective hedge accounting discontinue hedge ineffectiveness include current period earning company document relationship hedge item derivative overall risk management strategy include reason undertake hedge transaction enter derivative objective strategy minimize foreign currency exposure impact company financial performance protect company cash flow adverse movement foreign exchange rate ensure appropriateness financial instrument manage enterprise risk associate financial institution advertising cost associate advertising expense year incur advertising expense worldwide comprise television radio print medium internet advertising billion billion billion income taxis company intend continue reinv undistributed international earning expand international operation tax provide cover repatriation undistribute earning december december cumulative undistribute international earning approximately billion billion respectively net earning share basic earning share compute divide net income available common shareowner weight average number common share outstanding period dilute earning share reflect potential dilution occur security contract issue common stock exercise convert common stock risk uncertaintie preparation consolidated financial statement conformity accounting principle generally accept united states require management estimate assumption affect amount report actual result differ estimate annual closing date company follow concept fiscal year end sunday nearest end month december normally fiscal year consist week year case fiscal year consist week reclassification certain prior year amount reclassify conform current year presentation stock split april board director declare stock split shareowner record close business issue additional share johnson johnson common stock june share hold record date share share datum period present financial statement adjust reflect stock split inventory end inventory comprise table caption dollar million craw material supply good process finish good table property plant equipment end property plant equipment cost accumulate depreciation table caption dollar millions land land improvement building build equipment machinery equipment construction progress accumulate depreciation table company capitalize interest expense cost construction facility equipment interest expense capitalize million million million respectively retirement disposal fix asset cost relate accumulate depreciation amortization eliminate asset accumulate depreciation account respectively difference net asset value proceed adjust earning rental expense lease commitment rental space vehicle manufacture equipment office datum processing equipment operating lease amount approximately million million million approximate minimum rental payment require operating lease initial remain noncancelable lease term excess year december table caption dollar million total table commitment capital lease significant employee relate obligation end employee relate obligation table caption dollar millions post retirement benefit post employment benefit pension liability defer compensation employee relate obligation table borrowing component longterm debt follow table caption eff eff dollars millions rate rate zero coupon convertible subordinated debenture zero coupon convertible subordinated debenture convertible subordinated debenture debenture note debenture eurodollar note eurodollar note note deutsche mark note note industrial revenue bond principally international current portion table weight average effective rate represent deutsche mark note issue japanese subsidiary convert fix rate yen note currency swap represent dollar note issue japanese subsidiary convert fix rate yen note currency swap company access substantial source fund numerous bank worldwide total unused credit available company approximate billion include billion credit commitment bank worldwide expire october interest charge borrowing credit line agreement base bid provide bank prime rate london interbank offer rate libor plus applicable margin commitment fee agreement material company shelf registration file security exchange commission enable company issue billion unsecured debt security warrant purchase debt security medium term note mtn program mtn issue december company billion remain shelf registration long term debt include convertible subordinated debenture issue centocor alza prior respective merger johnson johnson respect convertible subordinated debenture originally issue centocor company exercise option redeem debenture set february redemption date price equal principal plus accrue interest debenture convert holder approximately million share johnson johnson stock conversion price share july alza complete private offering zero coupon convertible subordinated debenture issue price principal maturity december outstanding debenture total principal maturity billion yield maturity annum compute semiannual bond equivalent basis periodic interest payment term debenture holder entitle convert debenture approximately million share johnson johnson stock price share approximately share issue december voluntary conversion note holder option holder debenture repurchase company july purchase price equal issue price plus accrete original issue discount purchase date company option elect deliver johnson johnson common stock cash combination stock cash event repurchase debenture company option redeem debenture july issue price plus accrete original issue discount december december fair value base quote market value debenture million million respectively alza issue zero coupon convertible subordinated debenture price principal maturity december outstanding debenture total principal maturity million yield maturity annum compute semiannual bond equivalent basis periodic interest payment term debenture note holder entitle convert debenture approximately million share johnson johnson stock price share approximately million share johnson johnson stock issue december voluntary conversion note holder option holder debenture purchase company july july purchase price equal issue price plus accrete original issue discount purchase date company option elect deliver common stock cash event conversion purchase debenture company option redeem debenture cash july redemption price equal issue price plus accrete original issue discount december december fair value base quote market value debenture million million respectively shortterm borrowing current portion longterm debt amount million end borrowing comprise million note million local borrowing principally international subsidiary aggregate maturity longterm obligation commence table caption dollar millions table intangible asset end gross net amount intangible asset table caption dollar millions goodwill gross accumulate amortization goodwill net patent trademark gross accumulate amortization patent trademark net intangible gross accumulate amortization intangible net total intangible asset gross accumulate amortization total intangible asset net table weight average amortization period goodwill patent trademark intangible year year year respectively intangible asset include billion related acquisition complete june account new provision sfas sfas effect implementation new provision intangible record prior june reduction amortization expense approximately million prospectively refer note additional information income taxis provision taxis income consist table caption dollar millions currently payable tax international taxis defer taxis international taxis table comparison income tax expense federal statutory rate company effective tax rate follow table caption dollar millions international earning taxis income statutory taxis tax rate statutory puerto rico ireland operation research tax credit domestic state local international subsidiary exclude ireland iprd effective tax rate tabledure company subsidiary operate puerto rico tax incentive grant expiring addition company subsidiary manufacture ireland incentive tax rate effective year defer income taxis recognize tax consequence temporary difference apply enact statutory tax rate applicable future year difference financial reporting tax basis exist asset liability temporary difference carryforward follow table caption defer tax dollar million asset liability employee relate obligation depreciation nondeductible intangible international capitalize tax reserve liabilitie income report tax purpose miscellaneous international capitalize intangible miscellaneous total deferred income taxis table difference net defer tax income balance sheet net defer tax include taxis income balance sheet international currency translation translation nonus dollar currency company determine local currency international subsidiary functional currency highly inflationary economy define compound cumulative rate inflation past year consolidate international subsidiary balance sheet currency effect record component accumulate comprehensive income equity account include result translate balance sheet asset liability current exchange rate locate highly inflationary economy reflect operating result analysis change foreign currency translation adjustment include note net currency transaction translation gain loss include expense aftertax loss million million million respectively common stock stock option plan stock compensation agreement december company stockbase compensation plan stock option plan company grant option employee issue share company common stock plus number share available previous year issue share issue plan expired terminate exercised share outstanding contract company employee stock option plan nonemployee director plan mitek cordis biosense gynecare centocor innovasive device alza inverness stock option plan stock option expire year date grant vest service period range year option grant current market price date grant share available stock option plan future grant base issue share year million share grant year year addition available share describe share available future grant plan million theend summary status company stock option plan december december january change year end date present table caption weight option average share thousand outstanding exercise price balance january option grant option exercise option canceledforfeite balance january option grant option exercise option canceledforfeite balance december option grant option exercise option canceledforfeite balance december table include option issue replace inverness option outstanding grant prior acquisition year end december change timing grant stock compensation option employee december february change enact result finalize order align compensation performance company apply provision financial accounting standard accounting stockbase compensation call company measure employee stock compensation expense base fair value method accounting allow statement company elect continue use accounting principle board apb opinion accounting stock issue employee pro forma disclosure net income earning share determine fair value method apply measure compensation cost fair value method apply net income reduce million share million share million share calculation account option issue january average fair value option grant fair value estimate blackschole option pricing model base weighted average assumption table caption riskfree rate volatility expect life yrs yrs yrs dividend yield table follow table summarize stock option outstanding exercisable december table caption share thousand outstanding exercisable average average exercise average exercise exercise price range option lifea price option price table average contractual life remain year accumulate comprehensive income component comprehensive incomeloss consist follow table caption total unrealize gain accumulate foreign gain pension loss currency loss liability derivative comprehensive dollar million translation security adjustment hedge incomeloss jan changes jan change dec change transition adjustment net change hedging transaction net reclasse net earning net change dec table total comprehensive income include reclassification adjustment gain million realize sale equity security associate tax expense million total comprehensive income include reclassification adjustment gain million realize sale equity security associate tax expense million total comprehensive income include reclassification adjustment loss million associate tax benefit million tax effect unrealize gainslosses equity security expense million million million tax effect gainslosse derivative hedge expense million note additional information relate derivative hedge currency translation adjustment currently adjust income taxis relate permanent investment nonus subsidiary segment business geographic area information segment business geographic area retirement pension plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide company provide postretirement benefit primarily health care domestic retire employee dependent international employee cover government sponsor program cost company significant retirement plan benefit primarily base employee compensation year retirement number year service company objective fund domestic plan accumulate fund sufficient provide accrue benefit international subsidiary plan fund deposit trustee annuity purchase group contract reserve provide certain country united states fund pension plan common practice funding provide economic benefit consequently company pension plan fund company fund retiree health care benefit advance right modify plan future net periodic benefit cost company define benefit retirement plan benefit plan include follow component table caption retirement plan benefit plan dollar million service cost interest cost expect return plan asset amortization prior service cost amortization net transition asset recognize actuarial gainloss curtailment settlement net periodic benefit cost table net periodic income cost attributable domestic retirement plan million million million follow table provide weightedaverage assumption todevelop net periodic benefit cost actuarial present value project benefit obligation table caption retirement plan benefit plan domestic benefit plan weight average discount rate expect longterm rate return plan asset rate increase compensation level international benefit plan weight average discount rate expect longterm rate return plan asset rate increase compensation level table health care cost trends united states project annual rate individual grade year effect change assume cost trend accumulate postretirement benefit obligation end million increase million decrease effect service interest cost component net periodic postretirement benefit cost million increase million decrease follow table set forth change benefit obligation change plan asset yearend company define benefit retirement plan postretirement plan table caption dollar million retirement plan benefit plan change benefit obligation benefit obligation begin year service cost interest cost plan participant contribution amendment actuarial loss acquisition curtailment settlement total benefit pay effect exchange rate benefit obligation end year change plan asset plan asset fair value begin year actual return plan asset company contribution plan participant contribution acquisition benefit pay plan asset effect exchange rate plan asset fair value end year table amount recognize company balance sheet consist follow table caption retirement plan benefit plan dollar million plan asset excess project benefit obligation unrecognized actuarial gain unrecognize prior service cost unrecognized net transition asset total recognize consolidated balance sheet book reserve prepay benefit asset total recognize consolidated balance sheet table plan accumulate benefit obligation excess plan asset consist follow table caption retirement plan benefit plan dollar million accumulate benefit obligation project benefit obligation plan asset fair value table marketable security table caption december december dollar million amortize unrealize unrealized estimate amortize unrealize unrealized estimate cost gain loss fair value cost gain loss fair value money market fund commercial paper time deposit government security obligation asset back security bank note corporate debt security total current marketable security government security asset back security bank note corporate debt security investment hold trust total noncurrent marketable security table current marketable security include billion billion classified cash equivalent balance sheet december december respectively financial instrument effective january company adopt sfas require allderivative instrument record balance sheet fair value january company record million netoftax cumulative effect transition adjustment gain accumulate comprehensive income recognize fair value derivative instrument designate cash flow hedge adjustment net earning immaterial december balance defer net gain derivative include accumulate comprehensive income million tax company expect million reclassify earning month result transaction expect occur period ultimately realize earning differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity derivative primary type underlie transaction cause accumulate comprehensive income affect net earning primarily consist sale party maximum length time company hedge exposure variability future cash flow forecast transaction month year end december net impact hedge ineffectiveness company financial statement insignificant year end december company record net gain million tax income expense net category consolidate statement earning represent impact discontinuance cash flow hedge probable originally forecast transaction occur end originally specify time period refer note disclosure movement accumulate comprehensive income concentration credit risk company invest excess cash deposit major bank world high quality shortterm liquid money market instrument refer note additional information company policy make investment commercial institution equivalent credit rating investment generally mature month company incur relate loss company sell broad range product health care field country world ongoing credit evaluation customer financial condition perform generally collateral require sale distributor account total total company revenue company maintain reserve potential credit loss loss aggregate exceed management expectation saving plan company voluntary saving plan design enhance exist retirement program cover eligible employee company match percentage employee contribution consistent provision plan heshe eligible salary plan onethird company match pay company stock employee stock ownership plan esop establish esop company loan million esop trust purchase share company stock open market exchange company receive note balance record reduction shareowner equity total contribution plan million million million merger acquisition june johnson johnson alza corporation alza complete merger company transaction account poolingofinterest alza approximately million share outstanding million fully dilute basis exchange approximately million share johnson johnson common stock dilute basis adjust stock option convertible debt total number johnson johnson share issue total approximately million share holder alza common stock receive share johnson johnson common stock value share alza researchbased pharmaceutical company lead drugdelivery technology company apply delivery technology develop pharmaceutical product enhance therapeutic value portfolio world lead pharmaceutical company financial statement prepare retroactive effect johnson johnson merger alza adjustment alza historical financial statement reflection income tax expense company combine period present elimination transaction johnson johnson affiliate company reclassification certain amount conform johnson johnson presentation quarter revenue net earning johnson johnson prior merger alza billion billion respectively quarter revenue net earning alza include johnson johnson financial result million revenue million net earning revenue net earning johnson johnson prior merger alza billion billion respectively revenue billion billion respectively net earning revenue net earning alza include johnson johnson financial result million million respectively revenue million million respectively net earning year end december company incur million pretax million tax cost associate alza merger cost include incomeexpense net certain business acquire billion million cash debt assume approximately million share company common stock issuable treasury value billion acquisition account purchase method accordingly result operation include accompany consolidated financial statement respective date acquisition acquisition include inverness medical technology supplier lifescan electrochemical product blood glucose monitoring follow spinoff nondiabetes business heartport company develop manufacture product invasive open chest minimally invasive heart operation include stop heart beat heart procedure terame inc earlystage medical device company develop endovascular stentgraft system minimally invasive treatment abdominal aortic aneurysm peripheral occlusive disease babycentercom internet content commerce site devoted support community expectant new mother viactiv product line chewable calcium supplement mead johnson nutritional division bristolmyer squibb inverness medical technology acquire enhance control primary supplier lifescan blood glucose monitoring product allow achievement operational synergies acquisition provide key technology development future product preliminary purchase price allocation include current asset million property plant equipment million current liability million defer tax liability million long term debt million goodwill intangible asset acquire include million patent technology amortize period year annual amortization million year goodwill million accordance sfas goodwill intangible asset goodwill amortize deductible tax purpose approximately million identify value inprocess research development iprd associate inverness medical technology terame inc acquisition iprd charge primarily relate inverness project minimally invasive testing continuous monitoring insulin delivery value iprd calculate assistance party appraiser cash flow projection discount risk inherent project probability success factor range discount rate pro forma information provide impact acquisition material effect company result operation cash flow financial position certain business acquire million million cash debt assume approximately million share company common stock issue treasury value million acquisition account purchase method accordingly result operation include accompany consolidated financial statement respective date acquisition acquisition include crescendo company form alza purpose select develop commercialize human pharmaceutical product innovasive device company manufacture sell device sport medicine surgery soft tissue injury atrionix inc developmentstage company primary product pulmonary ablation catheter treatment atrial fibrillation medtrex company develop manufacture electrosurgical generator disposable product joseph aspirin business iprd writeoff associated atrionix inc alza crescendo acquisition million iprd charge primarily relate atrionix project design catheter system procedure block electrical impulse originate pulmonary vein cause atrial fibrillation value iprd calculate assistance party appraiser cash flow projection discount risk inherent project discount rate divestiture material effect company result operation cash flow financial position legal proceeding company involve numerous product liability case unite states concern adverse reaction drug medical device damage claim substantial company confident adequacy warning instruction use accompany product feasible predict ultimate outcome litigation company believe liability result case substantially cover reserve establish selfinsurance program commercially available excess liability insurance group case company concern janssen pharmaceutica product propulsid withdraw general sale restrict limited use wake publicity event lawsuit comprise claim name individual file janssen wholly own subsidiary company company propulsid state federal court country approximately plaintiff claim take propulsid rest derivative plaintiff spouse claim file patient die use propulsid significant number case seek certification class action action accuse janssen company inadequately testing warning drug effect promote offlabel use overpromotion action seek substantial compensatory punitive damage addition janssen company enter agreement plaintiff counsel halting run statute limitation respect potential claim significant number individual attorney evaluate sue janssen company behalf september plaintiff rankin case comprise claim plaintiff go trial state court claiborne county mississippi jury return compensatory damage verdict plaintiff million total million trial judge dismiss claim punitive damage janssen company believe verdict insupportable reduce post trial motion reverse appeal view janssen company proof trial demonstrate plaintiff injure propulsid basis liability exist respect propulsid action janssen company dispute claim lawsuit vigorously defend judgement settlement appropriate janssen company believe adequate self commercially available excess insurance respect case company ortho biotech subsidiary party arbitration proceeding file amgen ortho biotech licensor nondialysis right procriteprex amgen seek terminate ortho biotech license right collect substantial damage base allege deliberate procriteprex sales ortho biotech early amgen reserve dialysis market company believe basis exist terminate ortho biotech license right obtain damage vigorously contest amgen claim ortho biotech license right procriteprex material company unfavorable outcome termination issue material adverse effect company consolidated result operation cash flow financial position arbitration begin january expect conclude april arbitrator decision follow submission postheare brief side company lifescan subsidiary defendant class action file federal state court california allege purchaser surestep blood glucose meter stripssuffere economic harm product contain undisclosed defect late lifescan plead guilty federal court misdemeanor pay total million fine civil cost resolve investigation relate allege defect december action settle settlement preliminarily approve federal district court settlement account company material patent infringement action try delaware federal court late cordis johnson johnson company obtain verdict infringement patent validity damage awards boston scientific corporation medtronic ave inc base number cordis coronary stent patent december jury damage action boston scientific return verdict million december jury medtronic ave action return verdict million sum represent lose profit reasonable royalty damage compensate cordis infringement include pre post judgment interest february hearing hold claim boston scientific medtronic ave patent issue unenforceable owe allege inequitable conduct patent office post trial motion appeal federal circuit court appeal follow judgment likely pay proceeding run course furthermore damage company receive quantify legal process complete gain record financial statement award company involve number patent trademark lawsuit incidental business company believe proceeding note material adverse effect result operation cash flow financial position earning share follow reconciliation basic net earning share dilute net earning share year end december december january table caption share millions basic earning share average share outstanding basic potential share exercisable stock option plan share repurchase treasury stock method convertible debt share adjust average share outstanding diluted diluted earning share table dilute earning share calculation include dilution effect convertible debt decrease interest expense million million million tax year respectively dilute earning share exclude million share million share million share option year respectively exercise price option great average market value result antidilutive effect dilute earning share capital treasury stock change treasury stock table caption dollar million treasury stocknumber share thousand share balance january employee compensation stock option plan repurchase common stock business combination balance january employee compensation stock option plan conversion subordinate debenture repurchase common stock business combination balance december employee compensation stock option plan conversion subordinate debenture repurchase common stock business combination balance december table share common stock authorize issue share end share end share end select quarterly financial datum unaudite select unaudited quarterly financial datum year summarize table caption dollar million second fourth second fourth share amount quarter quarter quarter quarter quarter quarter quarter quarter segment sale customer consumer pharmaceutical med device diagnostic total sale gross profit earning provision taxis income net earning basic net earning share dilute net earning share table second quarter include tax charge million relate alza merger cost quarter include tax charge million relate alza merger cost fourth quarter include tax charge million relate inprocess research development iprd cost fourth quarter include tax charge million relate lifescan class action settlement fourth quarter include tax charge million relate iprd cost restructuring gain fourth quarter include tax charge million relate federal government investigation lifescan surestep blood glucose meter report management management johnson johnson responsible integrity objectivity accompany financial statement relate information statement prepare conformity accounting principle generally accept united states america include amount base good judgment consideration give materiality management maintain system internal accounting control monitor corporate staff professionally train internal auditor travel worldwide system design provide reasonable assurance reasonable cost asset safeguard transaction event record properly company organize principle decentralize management appropriate control measure evidence welldefine organizational responsibility management selection development evaluation process communicative technique financial planning reporting system formalize procedure policy practice company conduct affair ethically socially responsible manner responsibility characterize reflect company credo policy business conduct distribute company management maintain systematic program ensure compliance policy pricewaterhousecooper llp company independent auditor engage audit financial statement pricewaterhousecooper llp maintain understand internal control conduct test audit procedure consider necessary circumstance express opinion report follow audit committee board director compose solely outside director meet periodically independent auditor management internal auditor review work confirm properly discharge responsibility addition independent auditor general counsel vice president internal audit free meet audit committee presence management discuss result work observation adequacy internal financial control quality financial report relevant matter ralph larsen robert darretta ralph larsen robert darretta chairman board directors vice president finance chief executive officer chief financial officer independent auditor report shareowner board directors johnson johnson opinion accompany consolidated balance sheet relate consolidated statement earning consolidate statement equity consolidate statement cash flow present fairly material respect financial position johnson johnson subsidiaries december december result operation cashflow year period end december conformity accounting principle generally accept united states america financial statements responsibility company management responsibility express opinion financial statement base audit conduct audits statement accordance auditing standard generally accept united states america require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion pricewaterhousecooper llp new york new york january segments business johnson johnson subsidiaries table caption sale customer dollar million consumer domestic international total pharmaceutical domestic international total medical device diagnostic domestic international total worldwide total table table caption operating profit identifiable asset dollar million consumer pharmaceutical medical device diagnostic segment total expense allocate segment general corporate worldwide total table table caption addition property depreciation plant equipment amortization dollar millions consumer pharmaceutical medical device diagnostic segment total general corporate worldwide total table table caption geographic area sale customer longlive asset dollar million united states europe western hemisphere exclude asiapacific africa segment total general corporate non longlived asset worldwide total table management discussion analysis page description segment company business export sale intersegment sale significant sale distributor account total revenue sale concentrated pharmaceutical segment amount allocate segment include interest incomeexpense minority interest general corporate income expense general corporate include primarily cash marketable security include million alza merger cost pharmaceutical segment million inprocess research development iprd million class action settlement medical device diagnostic segment include restructure gain million consumer segment million million restructuring gain net iprd charge pharmaceutical medical device diagnostic segment respectively summary operation statistical data johnson johnson subsidiaries table caption dollar million share figure sale customer domestic sale customer international total sale cost product sell sell marketing administrative expense research expense purchase inprocess research development interest income interest expense net portion capitalize expense net special charge earning provision taxis income provision taxis income earning cumulative effect accounting change cumulative effect accounting change net tax net earning percent sale customer dilute net earning share common stock percent return average shareowner equity percent increase decrease previous year sale customer dilute net earning share supplementary expense datum cost material service total employment cost depreciation amortization maintenance repair total tax expense total tax expense share supplementary balance sheet datum property plant equipment net addition property plant equipment total asset longterm debt operate cash flow common stock information dividend pay share shareowner equity share market price share yearend close average share outstanding million basic diluted employee thousand table table caption dollar million share figure sale customer domestic sale customer international total sale cost product sell sell marketing administrative expense research expense purchase inprocess research development interest income interest expense net portion capitalize expense net special charge earning provision taxis income provision taxis income earning cumulative effect accounting change cumulative effect accounting change net tax net earning percent sale customer dilute net earning share common stock percent return average shareowner equity percent increase decrease previous year sale customer dilute net earning share supplementary expense datum cost material service total employment cost depreciation amortization maintenance repair total tax expense total tax expense share supplementary balance sheet datum property plant equipment net addition property plant equipment total asset longterm debt operate cash flow common stock information dividend pay share shareowner equity share market price share yearend close average share outstanding million basic diluted employee thousand table adjust reflect twoforone stock split exclude cumulative effect accounting change million earning percent sale customer accounting change earning share accounting change earning percent return average shareowner equity accounting change dilute net earning share percent increase prior year accounting change dilute net earning share increase prior year exclude special inprocess research development charge dilute net earning share special charge dilute net earning share increase prior year special charge earning percent sale customer special charge dilute net earning share special charge percent return average shareowner equity special charge dilute net earning share increase prior year special charge cost product sell include million inventory writeoff restructure diluted net earning share special charge exclude special charge dilute net earning share percent increase prior year diluted net earning share special charge exclude special charge dilute net earning share increase prior year diluted net earning share special charge exclude special charge dilute net earning share increase prior year period adjust include effect alza merger net interest income include cost material service category include taxis income payroll property business taxis share datum calculate average basic share text document document typeex sequence filenameyextxt descriptionsubsidiarie text exhibit subsidiary johnson johnson new jersey corporation domestic international subsidiary show certain domestic subsidiary international subsidiary name significant aggregate johnson johnson parent table caption jurisdiction subsidiary organization domestic subsidiary alza corporation delaware alza land management inc delaware angioguard inc delaware biosense webster inc california canam care corporation new york centocor inc pennsylvania codman shurtleff inc new jersey cordis corporation florida cordis international corporation delaware crescendo pharmaceuticals corporation delaware depuy inc delaware depuy acrome inc ohio depuy acrome sale limit partnership massachusetts depuy finance llc delaware depuy orthopaedics inc indiana depuy orthopaedic technology inc delaware diabetes diagnostics inc delaware ethicon endosurgery inc ohio ethicon endosurgery services texas ethicon inc new jersey ethicon llc delaware heartport inc delaware independence technology llc new jersey innovasive devices inc massachusetts janssen finance company florida janssen inc delaware janssen ortho llc delaware janssen pharmaceutica inc pennsylvania janssen pharmaceutica products new jersey janssen products inc delaware johnson johnson consumer company inc new jersey johnson johnson development corporation new jersey johnson johnson finance corporation new jersey johnson johnson health care systems inc new jersey johnson johnson international new jersey johnson johnson japan inc new jersey johnson johnson merck consumer pharmaceutical new jersey johnson johnson middle east inc new jersey johnson johnson pharmaceutical research development new jersey llc table table caption jurisdiction subsidiary organization johnson johnson professional inc delaware johnson johnson services inc new jerseyjohnson johnson vision care inc florida joint medical product corporation delaware jjhc inc delaware lifescan inc california lifescan llc delaware mcneilppc inc new jersey ndc investment corporation delaware neutrogena corporation delaware noramco inc georgia omj pharmaceuticals inc delaware ortho biologics llc delaware ortho biotech holding corp delaware ortho biotech inc new jersey ortho biotech products new jersey orthoclinical diagnostics inc new york orthomcneil finance florida orthomcneil pharmaceutical inc delaware terame corporation delaware tylenol company new jersey therakos inc florida winthorpe valentine inc delaware international subsidiary abello farmacia italy alza ireland limited ireland apsis france centra medicamenta otc srl italy cilag switzerland cilag international switzerland cilag mexico mexico cilag farmaceutica ltda brazil cilag holding switzerland cordis europa netherlands cordis medizinische apparate gmbh germany cordis mexico mexico cordis france cordis sarl switzerland depuy bioland france depuy france france depuy international ltd united kingdom depuy intl holdings ltd united kingdom depuy ireland limited ireland depuy japan japan depuy orthopadie gmbh germany depuy orthopedie france ethicon beteiligung gesellschaft mbh germany table table caption jurisdiction subsidiary organization ethicon endosurgery europe gmbh germany ethicon gmbh germany ethicon ireland limited ireland ethicon limited scotland ethicon sas france ethicon spa italy ethnor proprietary limited south africa greiter switzerland greiter international switzerland impulse dynamics ireland limited ireland inverness medical limited scotland janssen animal health bvba belgium janssencilag norway janssencilag sweden janssencilag switzerland janssencilag denmark janssencilag netherlands janssencilag egypt ltd egypt janssencilag venezuela janssencilag farmaceutica ltda brazil janssencilag farmaceutica ltda portugal janssencilag farmaceutica argentina janssencilag ltd united kingdom janssencilag belgium janssencilag finland janssencilag pharmaceutical saci greece janssencilag pharma gmbh austriajanssencilag pty limited australia janssencilag spain janssencilag france janssencilag spa italy janssen farmaceutica mexico janssencilag gmbh germany janssencilag international belgium janssen international belgium janssen korea ltd korea janssen ortho inc canada janssen pharmaceutica limited thailand janssen pharmaceutica belgium janssen pharmaceutica pty limited south africa janssen pharmaceutical japan janssen pharmaceutical limited ireland healthcare ltd israel jhc nederland netherlands jjmsd consumer pharmaceutical sas france johnson johnson switzerland johnson johnson denmark table table caption jurisdiction subsidiary organization johnson johnson mexico johnson johnson argentina sace argentina johnson johnson china investment ltd china johnson johnson china ltd china johnson johnson consumer france sas france johnson johnson consumer nvsa belgium johnson johnson colombia colombia johnson johnson del ecuador ecuador johnson johnson egypt sae egypt johnson johnson finance limited united kingdom johnson johnson financial services gmbh germany johnson johnson gmbh germany johnson johnson gesellschaft mbh austria johnson johnson hellas greece johnson johnson holding sweden johnson johnson holding gmbh germany johnson johnson hong kong limited hong kong johnson johnson inc canada johnson johnson industria comercio ltda brazil johnson johnson international financial services ireland company johnson johnson international france johnson johnson investments limited united kingdom johnson johnson ireland limited ireland johnson johnson kenya limited kenya johnson johnson kft hungary johnson johnson japan johnson johnson korea ltd korea johnson johnson lda portugal johnson johnson ltd united kingdom johnson johnson limited india johnson johnson msd consumer pharmaceutical sas france johnson johnson management ltd united kingdom johnson johnson medical netherlands johnson johnson medical china ltd china johnson johnson medical gmbh austria johnson johnson medical japan johnson johnson medical korea limited korea johnson johnson medical limited united kingdom johnson johnson medical mexico mexico johnson johnson medical nvsa belgium johnson johnson medical pty ltd australia johnson johnson medical argentina johnson johnson morocco morocco johnson johnson new zealand limited new zealand johnson johnson pacific pty ltd australia johnson johnson pakistan private limited pakistan johnson johnson philippines inc philippines table tablecaption jurisdiction subsidiary organization johnson johnson poland poland johnson johnson private limited zimbabwe johnson johnson products inc canada johnson johnson produtos profissionais ltda brazil johnson johnson professional product proprietary south africa ltd johnson johnson proprietary limited south africa johnson johnson pte ltd singapore johnson johnson pty limited australia johnson johnson research pty limited australia johnson johnson mexico johnson johnson spain johnson johnson sdn bhd malaysia johnson johnson spa italy johnson johnson spolsro czech republic johnson johnson taiwan ltd taiwan johnson johnson thailand ltd thailand johnson johnson venezuela venezuela johnson johnson vision products sweden johnson johnson vision products ireland ltd ireland johnson johnson zambia limited zambia laboratoires martin johnson johnson msd sas france laboratoire polive snc france lifescan canada ltd canada mcneil consumer nutritional europe switzerland medos switzerland neutrogena limited england neutrogena provence sarl france omj ireland limited ireland omj manufacturing ltd ireland orthoclinical diagnostic european support center france orthoclinical diagnostic gmbh germany orthoclinical diagnostic japan orthoclinical diagnostic united kingdom orthoclinical diagnostic spain orthoclinical diagnostic belgium orthoclinical diagnostic france orthoclinical diagnostic spa italy pharma argentina argentina johnson johnson indonesia indonesia shanghai johnson johnson pharmaceuticals ltd china shanghai johnson johnson ltd china surgikos mexico tasmanian alkaloid pty ltd australia johnson pharmaceutical research institute switzerland vania expansion snc france woelm pharma gmbh germany xianjanssen pharmaceutical limited china table text document document typeex sequence filenameyextxt descriptionconsent independent accountant text exhibit consent independent accountant consent incorporation reference registration statement johnson johnson form file form file form file relate prospectus report date january relate audit financial statement johnson johnson subsidiaries december december year period end december appear annual report shareowner incorporate annual report consent incorporation reference report date january relate financial statement schedule appear pricewaterhousecooper llp pricewaterhousecooper llp new york new york march text document document typeexb sequence filenameyexbtxt descriptioncautionary statement text exhibit cautionary statement pursuant private security litigation reform act safe harbor forwardlooke statement company time time certain forwardlooking statement publiclyrelease material write oral forwardlooking statement relate strictly historical current fact anticipate result base management plan subject uncertainty forwardlooke statement identify use word like plan expect anticipate estimate word similar meaning conjunction thing discussion future operation financial performance company strategy growth product development regulatory approval market position expenditure forwardlooke statement base current expectation future event company guarantee forwardlooke statement accurate company believe reasonable expectation assumption investor realize underlying assumption prove inaccurate unknown risk uncertainty materialize actual result vary materially company expectation projection investor caution place undue reliance forwardlooke statement furthermore company assume obligation update forwardlooke statement result new information future event development important factor cause company actual result differ company expectation forwardlooke statement follow economic factor include inflation fluctuation interest rate foreign currency exchange rate potential effect fluctuation revenue expense result margin competitive factor include technological advance achieve patent attain competitor challenge competitor company patent domestic foreign health care change result pricing pressure include continued consolidation health care provider trend manage care health care cost containment government law regulation relate sale promotion reimbursement pricing generally government law regulation affect domestic foreign operation include relate trade monetary fiscal policy taxis price control regulatory approval new product license patent right competition research involve development improvement new exist product process particularly significant result time time product process obsolescence development new improve product important company success area business difficulty inherent product development include potential inability successfully continue technological innovation complete clinical trial obtain regulatory approval united states abroad gain maintain market approval product possibility encounter infringement claim competitor respect patent intellectual property right preclude delay commercialization productsignificant litigation adverse company include product liability claim patent infringement claim antitrust claim arbitration proceeding file amgen terminate license right product efficacy safety concern result product recall regulatory action fda foreign counterpart decline sale impact business combination include acquisition divestiture internally company externally pharmaceutical health care industry issuance new revise accounting standard american institute certify public accountant financial accounting standard board securities exchange commission foregoing list set forth factor impact company ability achieve result describe forwardlooke statement investor understand possible predict identify factor consider list complete statement potential risk uncertainty company identify factor list permit private security litigation reform act text document secdocument end privacyenhance message